K65r in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4t or azt: Comparison of sanger and UDP sequencing data

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Recordon Pinson, Patricia ^a,b   Papuchon, Jennifer ^a,b   Reigadas, Sandrine ^a,b   Deshpande, Alaka ^c   Fleury, Hervé ^a,b  

^a CNRS   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c JJ Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RECEPTOR SUBTYPE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANALYTIC METHOD; ARTICLE; CODON; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; SANGER METHOD; TREATMENT FAILURE; ULTRADEEP PYROSEQUENCING; VIRUS ISOLATION; VIRUS MUTATION; COMPARATIVE STUDY; GENETICS; ISOLATION AND PURIFICATION; MUTATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 84861205409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036549     Document Type: Article

References (18)

1. Deshpande A, Jeannot AC, Schrive MH, Wittkop L, Pinson P, et al. (2010) Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. AIDS Res Hum Retroviruses 3: 343-350.
2. Kumarasamy N, Madhavan K, Venkatesh K, Saravanan S, Kantor R, et al. (2009) High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 49: 306-309.
3. Brenner BG, Coutsinos D, (2009) The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 3: 583-594.
4. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W, (2011) Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 83: 1764-1769.
5. Hawkins CA, Chaplin B, Idoko J, Ekong E, Adewole I, et al. (2009) Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 52: 228-234.
6. Pillay V, Pillay C, Kantor R, Venter F, Levin L, et al. (2008) HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 11: 1449-1454.
7. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. J AIDS Jun 1;23 (9): 1127-34.
8. Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, et al. (2006) High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 50: 4182-4185.
9. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, et al. (2009) Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 83: 2029-2033.
10. Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA, (2010) Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 20: 117-131.
11. Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez-Cajas JL, et al. (2011) A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 6: e20208.
12. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, et al. (2009) Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 200: 1202-1206.
13. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, et al. (2010) Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One 5: e10992.
14. Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, et al. (2011) Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antivir Ther 16: 925-929.
15. Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ, (2011) Drug Resistance Mutations in HIV Type 1 Isolates from Naive Patients Eligible for First Line Antiretroviral Therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. AIDS Res Hum Retroviruses 27: 1345-1347.
16. Shafer RW, (2009) Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis 199: 610-612.
17. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, et al. (2011) Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis 203: 798-802.
18. Toni TA, Brenner BG, Asahchop EL, Ntemgwa M, Moisi D, et al. (2010) Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1. Antimicrob Agents Chemother 54: 907-911.